How are bypass pathways selected for during ALK inhibitor treatment, can we predict which path of drug resistance a tumour is likely to exploit, and how do we target these pathways on an individual patient basis? Initial studies suggested a number of bypass pathways, and we have to build a clear picture of the overall signalling network. The gene discussed is ALK; the disease is neoplasm.